Avalo Therapeutics

Nasdaq: AVTX · SEC EDGAR filings

Results on file1
Average 24h move+33.83%across 1 result with a complete 24h price
1 resultAvalo Therapeutics
Met endpoint

Abdakibart

Phase 2 n=253 Hidradenitis Suppurativa

Avalo Therapeutics AVTX

24h stock move +33.83%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.